CD80/86 axis blocking agent abatacept, selected among 130 immunomodulators to be tested in ACTIV-1 IM, a large randomized clinical trial on hospitalized COVID-19 patients. The candidate drug will be tested against anti-TNF therapy, CCR2/5 inhibitor and placebo in relation to illness severity, recovery speed, mortality and hospital resource utilization.

Drug candidate for severe COVID-19 identified by IMIDomics and VHIR Rheumatology Group selected for NIH clinical trial

Leave a Reply

Your email address will not be published. Required fields are marked *